세계의 PCR 기술 시장 예측(-2030년) : 제품별, 기술별, 용도별, 최종사용자별, 지역별

The PCR technologies market is projected to reach USD 21.89 Billion by 2030 from USD 14.61 in 2024, growing at a CAGR of 7.0% during the forecast period. The market is growing due to numerous factors.Increasing cases of infectious diseases, and regular advancements in PCR technologies drives this market. Rising expenditure in research and development and increase in application of biomarker profiling to detect diseases are other factors. Additionally, the market growth is affected by inclusion of PCR technology with artificial intelligence.

"qPCR to account for largest market share in 2023."

A variant of the Polymerase Chain Reaction (PCR) called quantitative PCR (qPCR), sometimes referred to as real-time PCR, enables the simultaneous amplification and quantification of a particular DNA or RNA sequence. qPCR tracks the reaction in real time as it develops and provides quantitative information on the amount of target nucleic acid, in contrast to traditional PCR, which only identifies the presence of genetic material after the reaction is finished. The market is driven by the rising demand for qPCR instruments, the increasing prevalence of illnesses, and technical advances. Moreover, qPCR is a very specific and sensitive method for identifying and measuring nucleic acids, which makes it necessary for the diagnosis of infectious disorders.

"Diagnostic Laboratories to hold largest share in the market."

Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decrease cost, expedites testing methods, and improve precision and accuracy of diagnosis. Diagnostic labs require PCR identify and diagnose a variety of illnesses. These labs use PCR extensively because of its precision, sensitivity, and speed in diagnosing genetic abnormalities, and infectious diseases.

"North America to register largest share in 2023."

The largest share was hold by North America in 2023. North America comprise US and Canada.

The growth is supported by increase in drug development associated with genomics. Apart from that, government led initiatives and increase in funding and grants supports growth. The region also has strong presence of prominent players who support the growth of this market by carrying out strategic partnerships, collaborations, expansion and acquisitions. Wide application of PCR methods in hospitals and diagnostic labs of this region is also increasing the demand for microfluidics in North America.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3- 20%
• By Designation: C-level-- 35%, Director-level-25%, and Others-40%
• By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle East and Africa- 5%

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China) Becton, Dickinson and Company (US) and Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), Hologic Inc. (US),.

Research Coverage

The report comprise segmentation that includes end users, products, applications, and geographic regions. It also discusses the key drivers, restraints, opportunities, and challenges affecting the growth of the PCR technologies market. The research offers stakeholders an assessment of market potential and challenges, with a focus on key players and competitive landscapes. Additionally, micromarkets are assessed according to their overall to the microfluidics sector, growth patterns, and potential. The analysis estimates increase in market segment revenues, focusing on five regions.

Key Benefits of Buying the Report:

This research aids new and existing players in the PCR technologies market to assess the sustainability of their investments by offering detailed information. It offers a dataset to assist in making key decisions. The main advantage of this report includes risk evaluation and offering direction for investment decisions. Market segmentation as per the end-users and geographical areas is offered in the study, that provides analysis and insights. It also provides trends, obstacles, opportunities, and drivers, giving stakeholders the information they need to make strategic decisions.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges impacting the PCR technologies market growth: advanced technology and rise in prevalence of infectious diseases ; premium price of devices and strict regulations ; rise in number of diagnostic centers/labs.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.

Market Development: Details related to profitable markets: this research discussees the PCR technologies business in numerous regions.

Market Diversification: Detailed understanding of advanced products, unexplored areas, latest developments, and investment in the market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Agilent Technologies, Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH DESIGN
  • 2.2.1 SECONDARY RESEARCH
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key objectives of secondary research
    • 2.2.1.3 Key data from secondary sources
  • 2.2.2 PRIMARY RESEARCH
    • 2.2.2.1 Key primary sources
    • 2.2.2.2 Key objectives of primary research
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primaries
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Customer-based market estimation
    • 2.3.1.3 Top-down approach
    • 2.3.1.4 Primary interviews
  • 2.3.2 GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 STUDY ASSUMPTIONS
• 2.7 GROWTH ASSUMPTIONS
• 2.8 RISK ASSESSMENT
• 2.9 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PCR TECHNOLOGIES MARKET OVERVIEW
• 4.2 PCR TECHNOLOGIES MARKET, BY REGION, 2024 VS. 2030 (USD MILLION)
• 4.3 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY AND END USER, 2023 (USD MILLION)
• 4.4 PCR TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing outbreaks of infectious diseases/viral persistence
    • 5.2.1.2 Development of miniaturized and portable point-of-care testing devices
    • 5.2.1.3 Integration of PCR technology with automation and data analysis tools
    • 5.2.1.4 High demand for technologically advanced molecular diagnostics
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Premium product pricing
    • 5.2.2.2 Dearth of skilled healthcare professionals
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increased investments in laboratory infrastructure
    • 5.2.3.2 Rising number of applications in rare sequence detection
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Technical limitations
    • 5.2.4.2 Increased pricing pressure on market players
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & DEVELOPMENT
  • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.4 PORTER'S FIVE FORCES ANALYSIS
  • 5.4.1 THREAT OF NEW ENTRANTS
  • 5.4.2 THREAT OF SUBSTITUTES
  • 5.4.3 BARGAINING POWER OF SUPPLIERS
  • 5.4.4 BARGAINING POWER OF BUYERS
  • 5.4.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.5 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.5.2 KEY BUYING CRITERIA
• 5.6 PATENT ANALYSIS
  • 5.6.1 LIST OF MAJOR PATENTS
• 5.7 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.8 TRADE DATA ANALYSIS
  • 5.8.1 IMPORT DATA FOR HS CODE 3822
  • 5.8.2 EXPORT DATA FOR HS CODE 3822
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE OF REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2024
  • 5.9.2 INDICATIVE PRICING OF REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2024
  • 5.9.3 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2022-2024
  • 5.9.4 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2022-2024
• 5.10 UNMET NEEDS AND KEY PAIN POINTS
• 5.11 ECOSYSTEM ANALYSIS
• 5.12 SUPPLY CHAIN ANALYSIS
  • 5.12.1 MANUFACTURING COMPANIES
  • 5.12.2 SALES & DISTRIBUTION AGENTS
  • 5.12.3 END USERS
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.14 TECHNOLOGY ANALYSIS
  • 5.14.1 KEY TECHNOLOGIES
    • 5.14.1.1 Thermal cyclers
    • 5.14.1.2 Real-time quantitative PCR
    • 5.14.1.3 Portable and point-of-care PCR
  • 5.14.2 COMPLEMENTARY TECHNOLOGIES
    • 5.14.2.1 Next-generation sequencing
    • 5.14.2.2 Microarrays
    • 5.14.2.3 Lab-on-a-chip devices
    • 5.14.2.4 Robotics and automation
  • 5.14.3 ADJACENT TECHNOLOGIES
    • 5.14.3.1 Mass spectrometry
    • 5.14.3.2 Single-cell sequencing
    • 5.14.3.3 Fluorescence in situ hybridization
• 5.15 REGULATORY LANDSCAPE
  • 5.15.1 REGULATORY ANALYSIS
    • 5.15.1.1 North America
      • 5.15.1.1.1 US
      • 5.15.1.1.2 Canada
    • 5.15.1.2 Europe
    • 5.15.1.3 Asia Pacific
      • 5.15.1.3.1 Japan
      • 5.15.1.3.2 China
      • 5.15.1.3.3 India
  • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.16 INVESTMENT AND FUNDING SCENARIO
• 5.17 REIMBURSEMENT SCENARIO ANALYSIS
• 5.18 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET

6 PCR TECHNOLOGIES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 REAGENTS AND CONSUMABLES
  • 6.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH
• 6.4 SOFTWARE AND SERVICES
  • 6.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE FOR ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH

7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE

• 7.1 INTRODUCTION
• 7.2 REAL-TIME PCR
  • 7.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH
• 7.3 CONVENTIONAL PCR
  • 7.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH
• 7.4 DIGITAL PCR
  • 7.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION
• 7.5 REVERSE TRANSCRIPTION PCR
  • 7.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH
• 7.6 HOT-START PCR
  • 7.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH
• 7.7 MULTIPLEX PCR
  • 7.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH
• 7.8 OTHER PCR TECHNIQUES

8 PCR TECHNOLOGIES MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC APPLICATIONS
  • 8.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH
• 8.3 GENOTYPING
  • 8.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH
• 8.4 NUCLEIC ACID DETECTION
  • 8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH
• 8.5 GENE EXPRESSION ANALYSIS
  • 8.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH
• 8.6 NUCLEIC ACID SYNTHESIS
  • 8.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH
• 8.7 GENETIC SEQUENCING
  • 8.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH
• 8.8 ENVIRONMENTAL APPLICATIONS
  • 8.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR
• 8.9 STANDARD VALIDATION/VERIFICATION
  • 8.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET
• 8.10 OTHER APPLICATIONS

9 PCR TECHNOLOGIES MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITAL LABORATORIES
  • 9.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH
• 9.3 DIAGNOSTIC LABORATORIES
  • 9.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
• 9.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS
  • 9.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET
• 9.5 PHARMA-BIOTECH COMPANIES
  • 9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES
• 9.6 OTHER END USERS

10 PCR TECHNOLOGIES MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American PCR technologies market during study period
  • 10.2.3 CANADA
    • 10.2.3.1 Supportive government initiatives for genomics research to aid market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Presence of well-established pharmaceutical and R&D industry to augment market growth
  • 10.3.3 FRANCE
    • 10.3.3.1 Increasing investments in life science R&D for infrastructural development to favor market growth
  • 10.3.4 UK
    • 10.3.4.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Supportive government policies and high healthcare expenditure to boost market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Presence of large target patient population and high government healthcare expenditure to support market growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 High healthcare expenditure to drive adoption of advanced PCR technologies
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Improved medical tourism and prevalence of chronic diseases to propel market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Growing focus on proteomics and genomics research to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.4.1 GLOBAL PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • 11.4.2 GLOBAL PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2023
  • 11.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Product footprint
    • 11.5.5.3 Application footprint
    • 11.5.5.4 Technique footprint
    • 11.5.5.5 End user footprint
    • 11.5.5.6 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2023
    • 11.6.5.1 DETAILED LIST OF KEY startups/SMEs players
    • 11.6.5.2 Competitive benchmarking of key startups/SMEs
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025
• 11.8 PRODUCT/BRAND COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 THERMO FISHER SCIENTIFIC INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Services/Solutions offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches and approvals
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Services/Solutions offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches and approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 AGILENT TECHNOLOGIES, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Services/Solutions offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
      • 12.1.3.3.2 Other developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 BIO-RAD LABORATORIES, INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Services/Solutions offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 QIAGEN
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Services/Solutions offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches and approvals
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 DANAHER CORPORATION
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Services/Solutions offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product approvals
      • 12.1.6.3.2 Deals
      • 12.1.6.3.3 Expansions
  • 12.1.7 ABBOTT
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Services/Solutions offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product approvals
  • 12.1.8 TAKARA BIO INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Services/Solutions offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
      • 12.1.8.3.2 Deals
  • 12.1.9 ANALYTIK JENA GMBH+CO. KG
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Services/Solutions offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
  • 12.1.10 EPPENDORF SE
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Services/Solutions offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches and approvals
  • 12.1.11 MERCK KGAA
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products/Services/Solutions offered
  • 12.1.12 BIONEER CORPORATION
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products/Services/Solutions offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Other developments
  • 12.1.13 REVVITY
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products/Services/Solutions offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches
      • 12.1.13.3.2 Other developments
  • 12.1.14 BECTON, DICKINSON AND COMPANY
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products/Services/Solutions offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product launches and approvals
      • 12.1.14.3.2 Deals
  • 12.1.15 BIOMERIEUX
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products/Services/Solutions offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Product launches and approvals
  • 12.1.16 STANDARD BIOTOOLS
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products/Services/Solutions offered
  • 12.1.17 HOLOGIC, INC.
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products/Services/Solutions offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Product launches
  • 12.1.18 LONZA
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products/Services/Solutions offered
  • 12.1.19 ILLUMINA, INC.
    • 12.1.19.1 Business overview
    • 12.1.19.2 Products/Services/Solutions offered
  • 12.1.20 SANSURE BIOTECH INC.
    • 12.1.20.1 Business overview
    • 12.1.20.2 Products/Services/Solutions offered
• 12.2 OTHER PLAYERS
  • 12.2.1 PROMEGA CORPORATION
  • 12.2.2 LIMING BIO
  • 12.2.3 TRANSGEN BIOTECH CO., LTD.
  • 12.2.4 DAAN GENE CO., LTD.
  • 12.2.5 BIOBASE GROUP
  • 12.2.6 NIPPON GENETICS EUROPE
  • 12.2.7 STILLA
  • 12.2.8 GENSCRIPT
  • 12.2.9 NEW ENGLAND BIOLABS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS